ThredUp has been on fire lately. In the past six months alone, the company’s stock price has rocketed 489%, reaching $4.20 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Since October 2024, Qualys has been in a holding pattern, posting a small return of 2.8% while floating around $125.31. However, the stock is beating the S&P 500’s 5.3% decline during that period.
Kennametal’s stock price has taken a beating over the past six months, shedding 24.6% of its value and falling to $19.29 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at BlackLine (NASDAQ:BL) and its peers.
Since October 2024, Amplitude has been in a holding pattern, posting a small loss of 0.6% while floating around $8.96.
MDU Resources has gotten torched over the last six months - since October 2024, its stock price has dropped 42.8% to $16.95 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Jazz Pharmaceuticals currently trades at $109.85 per share and has shown little upside over the past six months, posting a small loss of 1.4%.
Since April 2020, the S&P 500 has delivered a total return of 92.4%. But one standout stock has nearly doubled the market - over the past five years, DistributionNOW has surged 162% to $15.52 per share. Its momentum hasn’t stopped as it’s also gained 29.5% in the last six months thanks to its solid quarterly results, beating the S&P by 34.9%.
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the consumer discretionary industry, including Churchill Downs (NASDAQ:CHDN) and its peers.
Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.